

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**3DMed**

**思路迪**

**3D Medicines Inc.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1244)**

## **VOLUNTARY ANNOUNCEMENT**

### **3D185 GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF GASTRIC CANCER AND GASTRO-ESOPHAGEAL JUNCTION CANCER**

This announcement is made by 3D Medicines Inc. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) on a voluntary basis to update shareholders of the Company and potential investors with the latest business development of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that on January 13, 2023, 3D185 was granted the orphan-drug designation by the United States Food and Drug Administration (the “**FDA**”) for the treatment of gastric cancer and gastro-esophageal junction cancer. This is the second orphan-drug designation granted to 3D185, and in October 2022, 3D185 also received an orphan-drug designation for the treatment of biliary tract cancer.

#### **About 3D185**

3D185 is a fibroblast growth factor receptors (FGFR) 1-3 and colony stimulating factor 1 receptor (CSF1R) inhibitor that is expected to inhibit the activity of type 1, 2 and 3 FGFR. A phase I clinical trial is currently underway in patients with advanced solid tumors who are refractory to standard therapy to evaluate its single-agent safety and tolerability.

#### **About FGFR**

The FGFR family is an important family of receptor tyrosine kinases, and abnormal FGFR pathways are closely related to the occurrence and development of many malignant tumors. Drugs targeting abnormal FGFR are the hotspots in the development of cancer treatment in the near future, and it is expected to provide more treatment options for cancer patients. 3D185 is a small molecule inhibitor of FGFR, which can selectively inhibit FGFR1, FGFR2 and FGFR3 kinases. Its antitumor activity has been confirmed in preclinical studies. Its highly selective characteristics have clear competitive advantages in avoiding potential toxicity of multi-target inhibition, selection of sensitive populations and design of combined drug regimens.

## **About Gastric Cancer**

Gastric cancer is one of the major health burdens worldwide. More than 90% of gastric cancers are adenocarcinomas. Gastroesophageal junction carcinoma anatomically spans the distal esophagus and proximal stomach. Gastroesophageal junction cancer is mostly adenocarcinoma, and because of its location, gastroesophageal junction cancer is often treated in combination with gastric cancer.

## **About Orphan Drugs**

“Orphan drugs”, also known as “rare drugs”, refer to drugs used for the prevention, treatment and diagnosis of rare diseases. The FDA orphan drug designation is only for the treatment of a disease with an incidence of less than 200,000 in the United States, or if the incidence exceeds 200,000 beyond expectations, the drug must pass sufficient non-clinical and clinical data to show that it can bring greater benefit than existing approved therapies.

**Warning under Rule 18A.05 and Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company may not be able to successfully develop and/or market 3D185.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**3D Medicines Inc.**  
**Dr. Gong Zhaolong**  
*Chairman of the Board*

Hong Kong  
January 13, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Pai, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.*